Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MK-0524
Laropiprant · 3 trials · 3 indications
Low Density Lipoprotein Cholesterol (LDL-C) after 12 weeks is calculated as the difference between week 12 measure and baseline measure divided by baseline measure \*100
The creatinine-normalized urine levels of 11-dTxB2 on Day 7 following a 7 day course of daily dosing in the overall 24 hour collection interval.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | laropiprant/niacin (MK0524A) |
| 2 | PLACEBO_COMPARATOR | placebo |
| Laropiprant | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| A | EXPERIMENTAL | ER niacin/laropiprant + Placebo to laropiprant |
| B | ACTIVE_COMPARATOR | ER niacin + Placebo to laropiprant |
| C | EXPERIMENTAL | laropiprant + Placebo to ER niacin/laropiprant |
| D | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| laropiprant/niacin (MK0524A) | DRUG | Treatment Period 1: one 20mg/1g tablet laropiprant/niacin once daily for 4 weeks Treatment Period 2: two 20mg/1g tablets laropiprant/niacin once daily for 8 weeks. All patients will receive placebo for a 4 week run-in period before randomization |
| Comparator: placebo | DRUG | Treatment Period 1: one 20mg/1g tablet placebo to laropiprant/niacin once daily for 4 weeks Treatment Period 2: two 20mg/1g tablets of placebo to laropiprant/niacin once daily for 8 weeks. All patients will receive placebo for a 4 week run-in period before randomization. |
| Laropiprant | DRUG | One 100-mg tablet orally once daily for 4 weeks |
| Placebo for Laropiprant | DRUG | One tablet orally once daily for 4 weeks |
| Comparator: niacin + laropiprant | DRUG | ER niacin 2 g/laropiprant 40 mg tablet once daily for 7 days |
| Comparator: niacin | DRUG | ER niacin 2 g tablet once daily for 7 days |
| Comparator: laropiprant | DRUG | laropiprant 40 mg once daily for 7 days |
Inclusion Criteria: * Patient is male or female between 18 and 70 years of age * Females of reproductive potential must agree to take acceptable contraceptive precautions for the duration of the study Exclusion Criteria: * Patient has a history of not being able to take niacin or niacin-containin...
Top 12 of 15 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 4 | PHASE3 | Enlicitide |
| Novartis AG Sponsored ADR | NVS | 14 | PHASE3 | Inclisiran, Pelacarsen, DII235, QCZ484 |
| AstraZeneca PLC | AZN | 3 | PHASE3 | AZD0780, Laroprovstat, Rosuvastatin |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 5 | PHASE3 | Plozasiran, zodasiran, VSA003 |
| Ionis Pharmaceuticals, Inc. | IONS | 2 | PHASE3 | Olezarsen, ION775 |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE2 | Alirocumab |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Solbinsiran |
| MediciNova, Inc. | MNOV | 1 | PHASE2 | MN-001 |
| Verve Therapeutics, Inc. | VERV | 4 | PHASE2 | VERVE-102, VERVE-201 |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE1 | Obicetrapib |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
| Esperion Therapeutics, Inc. | ESPR | 1 | - | Bempedoic acid+ Ezetimibe |
Laropiprant is a small molecule being studied for the treatment of hypercholesterolemia and rosacea. It is an investigational drug developed by Merck & Company, Inc. (MRK) and is currently in Phase 1 clinical development for these indications.
Laropiprant is a small molecule that has been studied for its effects on cholesterol levels in patients with hypercholesterolemia and hyperlipidemia. Its specific molecular target has not been disclosed in available clinical trial information.
Laropiprant is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company has conducted clinical trials to evaluate the drug's safety and efficacy.
Laropiprant is currently in Phase 1 clinical development. It has completed a Phase 1 trial in participants with moderate to severe erythematotelangiectatic rosacea. The drug is investigational and has not been approved by regulatory authorities.
Laropiprant has been studied in two completed clinical trials. NCT00536510 was a Phase 3 study evaluating its effect on cholesterol levels in 646 participants with hypercholesterolemia and hyperlipidemia. NCT01451619 was a Phase 1 study in 60 participants with moderate to severe erythematotelangiectatic rosacea.
Laropiprant is also known as MK-0524. In clinical trials, the drug has been referred to by both names, including in a study of participants with rosacea (MK-0524-155) and a study of cholesterol levels (0524A-048).